Viral therapy for glioblastoma

Cancer Journal

Volumn 9, Issue 3, 2003, Pages 167-179

  Chiocca, E Antonio ^a   Aghi, Manish ^a   Fulci, Giulia ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; ANTIVIRUS AGENT; BETA GALACTOSIDASE; BETA INTERFERON; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; DACTINOMYCIN; DOXORUBICIN; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS VECTOR; MULTIDRUG RESISTANCE PROTEIN 1; ONCOLYTIC VIRUS; ORNITHINE CARBAMOYLTRANSFERASE; PACLITAXEL; PARVOVIRUS VECTOR; PROTEIN P53; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RETROVIRUS VECTOR; SOMATOMEDIN C; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA; VINCRISTINE; VIRUS VECTOR; ANTINEOPLASTIC AGENT;

ABSENCE OF SIDE EFFECTS; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BRAIN CANCER; BRAIN TUMOR; BREAST CANCER; CHROMOSOME 19Q; CLINICAL TRIAL; CONFUSION; CRANIOTOMY; DISSEMINATED INTRAVASCULAR CLOTTING; DNA MODIFICATION; ENCEPHALITIS; GENE MUTATION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HYPONATREMIA; MELANOMA; MESOTHELIOMA; METHODOLOGY; MULTIPLE MYELOMA; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; REVIEW; RNA VIRUS; SEIZURE; STATISTICAL SIGNIFICANCE; VIRAL GENE THERAPY; VIRUS REPLICATION; ADENO ASSOCIATED VIRUS; ADENOVIRUS; DRUG EFFECT; GENE THERAPY; GENE VECTOR; GENETICS; HERPES VIRUS; ORTHOREOVIRUS; RETROVIRUS; TRANSGENE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DEPENDOVIRUS; FLUCYTOSINE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HERPESVIRIDAE; HUMANS; MAMMALIAN ORTHOREOVIRUS 3; RETROVIRIDAE; TRANSGENES;

EID: 33749618683     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200305000-00005     Document Type: Review

References (92)

1. Macdonald DR. Temozolomide for recurrent high-grade glioma. Semin Oncol 2001;28:3-12.
2. Brem H et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-1012.
3. Kramm CM et al. Gene therapy for brain tumors. Brain Pathol 1995;5:345-381.
4. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-950.
5. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-1552.
6. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2:148-164.
7. Gene therapy clinical trials. J Gene Med 2001 http://www.wiley.co.uk/genetherapy/clinical/.
8. Zwiebel JA. Cancer gene and oncolytic virus therapy. Semin Oncol 2001;28:336-443.
9. Hu WS, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev 2000;52:493-511.
10. Chang LJ, Gay EE. The molecular genetics of lentiviral vectors: current and future perspectives. Curr Gene Ther 2001;1:237-251.
11. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983;33:153-159.
12. Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirus-mediated gene transfer. Curr Gene Ther 2001;1:101-122.
13. Wang II, Huang II. Adenovirus technology for gene manipulation and functional studies. Drug Discov Today 2000;5:10-16.
14. Alavi JB, Eck SL. Gene therapy for high grade gliomas. Expert Opin Biol Ther 2001;1:239-252.
15. Amalfitano A, Parks RJ. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther 2002;2:111-133.
16. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-376.
17. Kirn DH, McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today 1996;2:519-527.
18. Hollstein M et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-3555.
19. Rutka JT et al. Alterations of the p53 and pRB pathways in human astrocytoma. Brain Tumor Pathol 2000;17:65-70.
20. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-737.
21. Fueyo J et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
22. Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-1139.
23. Suzuki K et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-126.
24. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002;13:3-13.
25. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia 1999;1:402-416.
26. Pyles RB, Warnick RE, Chalk CL et al. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997;8:533-544.
27. Boviatsis EJ et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1994;1:323-331.
28. Markert JM, Malick A, Coen DM et al. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993;32:597-603.
29. Mineta T, Rabkin SD, Yazaki T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-943.
30. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-874.
31. Rabinowitz JE, Samulski RJ. Building a better vector: the manipulation of AAV virions. Virology 2000;278:301-308.
32. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000;6:433-440.
33. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? Gene Ther 2000;7:24-30.
34. Kapturczak MH, Flotte T, Atkinson MA. Adeno-associated virus (AAV) as a vehicle for therapeutic gene delivery: improvements in vector design and viral production enhance potential to prolong graft survival in pancreatic islet cell transplantation for the reversal of type 1 diabetes. Curr Mol Med 2001;1:245-258.
35. Coffey MC, Strong JE, Forsyth PA et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-1334.
36. Norman KL et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002;13:641-652.
37. Wilcox ME et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001;93:903-912.
38. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1999;1:44-51.
39. Mercer WE et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 1990;87:6166-6170.
40. Asai A et al. Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol 1994;19:259-268.
41. Roth JA et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-991.
42. Redemann N et al. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol 1992;12:491-498.
43. Van Meir EG et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994;8:171-176.
44. Millauer B, Shawver LK, Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-579.
45. Ma HI et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res 2002;62:756-763.
46. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
47. Gansbacher B et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-1224.
48. Yu JS,Wei MX, Chiocca EA et al. Treatment of gliomaby engineered interleukin 4-secreting cells. Cancer Res 1993;53:3125-3128.
49. Gansbacher B et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-7825.
50. Parker JN et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000;97:2208-2213.
51. Qin XQ et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998;95:14411-14416.
52. Tada H et al. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001;108:83-95.
53. Tjuvajev J et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 1995;55:1902-1910.
54. Herrlinger U et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1997;4:345-352.
55. Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39:597-638.
56. Shewach DS et al. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther 1994;1:107-112.
57. Freeman SM et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-5283.
58. Ishii-Morita H et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997;4:244-251.
59. Fick J et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995;92:11071-11075.
60. Ram Z et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 1994;81:256-260.
61. Barba D, Hardin J, Sadelain M et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994;91:4348-4352.
62. Gagandeep S et al. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect." Cancer Gene Ther 1996;3:83-88.
63. Kianmanesh AR et al. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 1997;8:1807-1814.
64. Kim JH et al. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 1995;33:861-868.
65. Jacobs A et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001;61:2983-2995.
66. Grem JL. 5-fluoropyrimidines. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: Lippincott, 1996:149-212.
67. Aghi M, Kramm CM, Chou TC et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998;90:370-380.
68. Mullen CA, Coale MM, Lowe R et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 1994;54:1503-1506.
69. Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res 1996;56:1361-1366.
70. Miller CR, Williams CR, Buchsbaum DJ et al. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002;62:773-780.
71. Dong Y et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996;7:713-720.
72. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 1989;49:2344-2350.
73. Wei MX et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994;5:969-978.
74. Wei MX, Tamiya T, Rhee RJ et al. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1995;1:1171-1177.
75. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 1997;57:4830-4837.
76. Aghi M, Chou TC, Suling K et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999;59:3861-3865.
77. Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-1361.
78. Klatzmann D et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998;9:2595-2604.
79. Packer RJ et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 2000;92:249-254.
80. Shand N et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999;10:2325-2335.
81. Harsh GR et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 2000;92:804-811.
82. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11:2389-2401.
83. Palu G et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther 1999;6:330-337.
84. Trask TW et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1:195-203.
85. Sandmair AM et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-2205.
86. Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-866.
87. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial [see comments]. Gene Ther 2000;7:867-874.
88. Herrlinger U et al. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 2000;1:347-357.
89. Rutka JT et al. Molecular biology and neurosurgery in the third millennium. Neurosurgery 2000;46:1034-1051.
90. Eck SL et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. Hum Gene Ther 2001;12:97-113.
91. Puumalainen AM, Vapalahti M, Agrawal RS et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Thur 1998;9:1769-1774.
92. Eck SL, Alavi JB, Alavi A et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSUTH: A phase I trial. Hum Gene Ter 1996;7:1465-1482.